JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65
Benzinga Newsdesk 15 minutes ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $70 to $65.
JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $70 to $65.